室性心律失常是导致心脏性猝死的重要原因之一。钠-葡萄糖共转运蛋白2（SGLT2）抑制剂可以减少室性心律失常的发生。上市的SGLT2抑制剂有达格列净、恩格列净、卡格列净和艾托格列净。SGLT2抑制剂临床用于治疗室性心律失常，其作用机制为影响离子通道、线粒体和氧化应激、心肌纤维化、低血糖和QT间期、能量代谢。总结了SGLT2抑制剂治疗室性心律失常的临床研究和作用机制，为开拓室性心律失常的治疗提供新思路。

Ventricular arrhythmia is one of the important causes of sudden cardiac death. Sodium-glucose cotransporter 2 (SGLT2) inhibitors can reduce the occurrence of ventricular arrhythmias. The SGLT2 inhibitors available for sale on the market include dapagliflozin, enagliflozin, canagliflozin, and etogliflozin. SGLT2 inhibitors are clinically used to treat ventricular arrhythmias, and their mechanisms of action include affecting ion channels, mitochondria and oxidative stress, myocardial fibrosis, hypoglycemia and QT interval, and energy metabolism. This article summarizes the clinical research and mechanism of action of SGLT2 inhibitors in treatment of ventricular arrhythmias, providing new ideas for exploring the treatment of ventricular arrhythmias.

R972

苏州市吴江区“科技兴卫”项目（WWK202213）